Advertisement
Advertisement
Dr. Axe Wire · Advanced therapies · health
Systematic Review Finds Only 30 Humans Studied For BPC-157 Safety
A new review of all human research on the popular healing peptide BPC-157 found only three small studies and very low certainty of evidence.
A systematic review published October 8, 2026 in Acta Orthopaedica Belgica found that the entire human evidence base for the injury-recovery peptide BPC-157 consists of just three small studies covering 30 people total.
Researchers searched Embase, PubMed, the Cochrane Library and ClinicalTrials registry through June 1, 2026 and identified only three human studies meeting criteria for this PRISMA-compliant, PROSPERO-registered review. One retrospective study gave 16 people intra-articular (into-the-joint) BPC-157 injections for knee pain. A second retrospective pilot study gave 12 people BPC-157 instilled directly into the bladder for interstitial cystitis, a chronic bladder pain condition. A third prospective pilot study tested intravenous BPC-157 safety in 2 people. All three studies reported symptom improvement in most participants, and none reported treatment-related adverse events. Using the NIH quality tool for before-after studies without a control group, the authors judged all three studies poor in methodological quality and rated overall certainty of evidence very low due to serious risk of bias, indirect comparisons and imprecise results from the small sample sizes.
BPC-157 is marketed as a tissue-repair peptide, derived from a protein found in stomach juice, that proponents say speeds healing of tendons, ligaments and gut lining. The authors note it lacks regulatory approval for human use and that evidence has been largely limited to animal models. None of the three studies had a comparison group, so any link between the peptide and symptom improvement is not proof that BPC-157 caused the improvement rather than natural healing or other treatment.
Advertisement
Review timeline for human BPC-157 evidence
- Database search cutoff (Embase, PubMed, Cochrane Library, ClinicalTrials.gov)
- Systematic review published in Acta Orthopaedica Belgica
With no control arm in any study, reported improvement cannot be separated from placebo response or the normal course of healing. The authors conclude the peptide needs ethically approved, regulated, high-quality clinical trials before any clinical use outside that setting.
Dr. Axe’s Take
This review shows BPC-157's popularity has run far ahead of the human evidence. Thirty people across three uncontrolled studies is not enough to know whether this peptide actually speeds tissue repair or whether people felt better for other reasons, including normal recovery time. I would not use BPC-157 outside a supervised clinical trial right now. For joint and gut healing, I'd focus on proven approaches first: adequate protein, collagen-rich foods like bone broth, omega-3s, and controlled loading through physical therapy. If you're using a prescribed medication for pain or inflammation, keep taking it as directed and talk with your doctor before adding any unregulated peptide.
— Dr. AxeStory summary
- Who
- 30 total human participants across three studies: 16 with knee pain, 12 with interstitial cystitis, 2 in a safety study
- Design
- Systematic review (PRISMA-compliant, PROSPERO-registered) of retrospective and prospective pilot studies, searched through June 1, 2026
- Dose
- Intra-articular injection (knee study), intravesical instillation (bladder study), intravenous administration (safety study); specific doses not reported
- Primary result
- Symptom improvement reported in most participants across all three studies; no treatment-related adverse events reported
- Secondary
- Overall certainty of evidence rated very low due to serious risk of bias, indirectness and imprecision; all three studies judged poor methodological quality
- Funding / conflicts
- Funding and conflicts not reported in the abstract.
- Date
- Oct 8, 2026